SVB Leerink analyst Joseph Schwartz downgraded The Medicines Company (NASDAQ: MDCO) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst PT Change Downgrades

Form 8-K MEDICINES CO /DE For: Nov 23November 25, 2019 6:36 AM Baird Downgrades The Medicines Company (MDCO) to NeutralNovember 25, 2019 4:15 AM UPDATE: Baird Upgrades Arrowhead Research (ARWR) to OutperformNovember 25, 2019 4:15 AM Oppenheimer Downgrades The Medicines Company (MDCO) to PerformNovember 25, 2019 4:14 AM Medicines Co. (MDCO) call put ratio 5.9 calls to 1 put with focus on December 75 and 85 calls into Novartis (NVS) dealNovember 25, 2019 3:48 AM Medicines Co. (MDCO) call put ratio 5.9 calls to 1 put into acquired by Novartis for $9.7BNovember 25, 2019 3:45 AM Transatlantic dealmaking sends European shares back to four-year peakNovember 25, 2019 3:37 AM Medicines Co. (MDCO) Agrees to be Acquired by Novartis AG (NVS) for $9.7B, or $85/ShareNovember 24, 2019 4:42 PM Novartis takes on Sanofi, Amgen with $9.7 billion takeover of heart drug makerNovember 24, 2019 4:00 PM The Medicines Company Enters Into Definitive Agreement to be Acquired by Novartis AG for $9.7 BillionNovember 24, 2019 3:05 PM Novartis to acquire The Medicines Company for USD 9.7 bn, adding inclisiran, a potentially transformational investigational cholesterol-lowering therapy to address leading global cause of deathNovember 24, 2019 3:00 PM Novartis nears deal to buy U.S. biotech firm Medicines Co for about $7 billion: WSJNovember 23, 2019 2:32 PM